ARS Pharmaceuticals, Inc. (SPRY)
Form 4 sales, Form 144 notices and lockup dates
- Latest sale
- $250k
- Jun 12 · Routine
- Form 4 sales
- 88
- On record
- Form 144 notices
- 20
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleRoutineJul 1 2025
Sold 15,000 shares at $16.99 ($255k)
Karas Eric, Chief Commercial Officer
10b5-1 planSold 59.3% of holdings ($430k position)10,315 shares left1.5x usual sizeFiling
- 2 Form 4 saleRoutineAug 20 +50 days
Sold 50,000 shares at $14.08 ($704k)
Tanimoto Sarina, CHIEF MEDICAL OFFICER
10b5-1 planSold 3.9% of holdings ($18.3M position)1.2M shares left0.5x usual sizeFiling
- 3 Form 4 saleRoutineAug 21 +1 day
Sold 12,500 shares at $15.00 ($188k)
Scott Kathleen D., Chief Financial Officer
10b5-1 planSold 55.5% of holdings ($338k position)10,042 shares left1x usual sizeFiling
- 4 Form 4 saleRoutineAug 21 same day
Sold 50,000 shares at $14.49 ($725k)
Lowenthal Richard E, PRESIDENT AND CEO
10b5-1 planSold 4% of holdings ($18.1M position)1.2M shares left0.5x usual sizeFiling
- 5 Form 4 saleUnusualNov 12 +83 days
Sold 166,380 shares at $8.87 ($1.5M)
Chakma Justin, Chief Business Officer
No 10b5-1 planSold 100% of holdings ($1.5M position)0 shares left1.7x usual sizeFiling
- 6 Form 4 saleUnusualNov 13 +1 day
Sold 21,828 shares at $8.71 ($190k)
Dorsey Brian, Chief Operating Officer
No 10b5-1 planSold 66.9% of holdings ($284k position)10,789 shares left0.5x usual sizeFiling
- 7 Form 4 saleRoutineJun 12 +211 days
Sold 3,355 shares at $10.00 ($34k)
Fitzpatrick Alexander A, Chief Legal Officer
10b5-1 planSold 3.6% of holdings ($943k position)90,910 shares leftFiling
- 8 Form 4 saleRoutineJun 12 same day
Sold 25,000 shares at $10.00 ($250k)
Karas Eric, Chief Commercial Officer
10b5-1 planSold 67.2% of holdings ($372k position)12,176 shares left2.5x usual sizeFiling
Every transaction
Loading transactions…
Sales, notices and lockups (108)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | Karas Eric | Chief Commercial Officer | Form 4 sale | 25,000 | $250k | 67.2% | Routine | SEC |
| Jun 12, 2026 | Fitzpatrick Alexander A | Chief Legal Officer | Form 4 sale | 3,355 | $34k | 3.6% | Routine | SEC |
| Nov 13, 2025 | Dorsey Brian | Chief Operating Officer | Form 4 sale | 21,828 | $190k | 66.9% | Unusual | SEC |
| Nov 12, 2025 | Chakma Justin | Chief Business Officer | Form 4 sale | 166,380 | $1.5M | 100.0% | Unusual | SEC |
| Aug 21, 2025 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 50,000 | $725k | 4.0% | Routine | SEC |
| Aug 21, 2025 | Scott Kathleen D. | Chief Financial Officer | Form 4 sale | 12,500 | $188k | 55.5% | Routine | SEC |
| Aug 20, 2025 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 50,000 | $704k | 3.9% | Routine | SEC |
| Jul 1, 2025 | Karas Eric | Chief Commercial Officer | Form 4 sale | 15,000 | $255k | 59.3% | Routine | SEC |
| Jun 27, 2025 | Flynn James E | 10% owner | Form 4 sale | 740,149 | $13.7M | 13.2% | No plan | SEC |
| Jun 18, 2025 | Karas Eric | Chief Commercial Officer | Form 4 sale | 15,000 | $240k | 66.1% | Routine | SEC |
| May 20, 2025 | Fitzpatrick Alexander A | Chief Legal Officer | Form 4 sale | 102,969 | $1.5M | 53.5% | Unusual | SEC |
| May 20, 2025 | Saunders Brent L | Director | Form 4 sale | 120,000 | $1.7M | 100.0% | Unusual | SEC |
| May 20, 2025 | Scott Kathleen D. | Chief Financial Officer | Form 4 sale | 50,000 | $705k | 87.1% | Unusual | SEC |
| Apr 7, 2025 | Shawver Laura | Director | Form 4 sale | 50,002 | $615k | 19.2% | Routine | SEC |
| Mar 20, 2025 | Karas Eric | Chief Commercial Officer | Form 4 sale | 10,000 | $140k | 56.5% | Routine | SEC |
| Mar 6, 2025 | Shawver Laura | Director | Form 4 sale | 50,000 | $560k | 19.2% | Routine | SEC |
| Feb 3, 2025 | Shawver Laura | Director | Form 4 sale | 50,000 | $616k | 19.2% | Routine | SEC |
| Jan 6, 2025 | Shawver Laura | Director | Form 4 sale | 50,000 | $555k | 19.2% | Routine | SEC |
| Dec 17, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 100,000 | $1.2M | 8.3% | Routine | SEC |
| Dec 17, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 100,000 | $1.2M | 8.3% | Routine | SEC |
| Dec 13, 2024 | Chakma Justin | Chief Business Officer | Form 4 sale | 144,605 | $1.8M | 51.5% | Unusual | SEC |
| Dec 13, 2024 | Chakma Justin | Officer | Form 144 notice | 27,272 | $329k | Notice | SEC | |
| Dec 12, 2024 | Dorsey Brian | Chief Operating Officer | Form 4 sale | 40,000 | $494k | 86.9% | Routine | SEC |
| Dec 12, 2024 | Chakma Justin | Officer | Form 144 notice | 117,333 | $1.3M | Notice | SEC | |
| Dec 11, 2024 | Dorsey Brian | Officer | Form 144 notice | 61,200 | $815k | Notice | SEC | |
| Dec 10, 2024 | Chakma Justin | Chief Business Officer | Form 4 sale | 50,000 | $658k | 26.8% | Unusual | SEC |
| Dec 10, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 100,000 | $1.3M | 8.0% | Routine | SEC |
| Dec 10, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 100,000 | $1.3M | 8.0% | Routine | SEC |
| Dec 10, 2024 | Chakma Justin | Director | Form 144 notice | 50,000 | $701k | Notice | SEC | |
| Dec 10, 2024 | Lowenthal Richard E | Officer, Director, Member of immediate family of any of the foregoing | Form 144 notice | 300,000 | $4M | Notice | SEC | |
| Dec 6, 2024 | Chakma Justin | Chief Business Officer | Form 4 sale | 144,640 | $2M | 51.5% | Unusual | SEC |
| Dec 6, 2024 | Chakma Justin | Officer | Form 144 notice | 50,000 | $700k | Notice | SEC | |
| Dec 5, 2024 | Chakma Justin | Officer | Form 144 notice | 49,640 | $661k | Notice | SEC | |
| Dec 4, 2024 | Shawver Laura | Director | Form 4 sale | 200,000 | $2.7M | 48.7% | Routine | SEC |
| Dec 4, 2024 | Karas Eric | Chief Commercial Officer | Form 4 sale | 10,000 | $140k | 63.7% | Routine | SEC |
| Dec 4, 2024 | Karas Eric | Officer | Form 144 notice | 6,283 | $88k | Notice | SEC | |
| Dec 4, 2024 | Chakma Justin | Officer | Form 144 notice | 45,000 | $653k | Notice | SEC | |
| Dec 3, 2024 | Chakma Justin | Chief Business Officer | Form 4 sale | 90,000 | $1.2M | 39.8% | Unusual | SEC |
| Dec 3, 2024 | Chakma Justin | Officer | Form 144 notice | 45,000 | $585k | Notice | SEC | |
| Dec 2, 2024 | Chakma Justin | Officer | Form 144 notice | 45,000 | $653k | Notice | SEC | |
| Dec 2, 2024 | Shawver Laura | Director | Form 144 notice | 200,000 | $2.7M | Notice | SEC | |
| Dec 2, 2024 | Karas Eric | Officer | Form 144 notice | 3,717 | $52k | Notice | SEC | |
| Nov 27, 2024 | Chakma Justin | Chief Business Officer | Form 4 sale | 100,000 | $1.4M | 42.3% | Unusual | SEC |
| Nov 19, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 100,000 | $1.4M | 7.7% | Routine | SEC |
| Nov 19, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 100,000 | $1.4M | 7.7% | Routine | SEC |
| Nov 12, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 100,000 | $1.7M | 7.4% | Routine | SEC |
| Nov 12, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 100,000 | $1.7M | 7.4% | Routine | SEC |
| Nov 12, 2024 | Deerfield Private Design Fund III, L.P. | 10% owner | Form 4 sale | 563,270 | $10.1M | 9.7% | No plan | SEC |
| Oct 16, 2024 | Scott Kathleen D. | Chief Financial Officer | Form 4 sale | 12,500 | $200k | 71.6% | Routine | SEC |
| Oct 15, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 100,000 | $1.5M | 7.2% | Routine | SEC |
| Oct 15, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 100,000 | $1.5M | 7.2% | Routine | SEC |
| Oct 8, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 100,000 | $1.4M | 6.9% | Routine | SEC |
| Oct 8, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 100,000 | $1.4M | 6.9% | Routine | SEC |
| Sep 18, 2024 | Karas Eric | Chief Commercial Officer | Form 4 sale | 10,000 | $140k | 63.7% | Routine | SEC |
| Sep 17, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 100,000 | $1.3M | 6.7% | Routine | SEC |
| Sep 17, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 100,000 | $1.3M | 6.7% | Routine | SEC |
| Sep 10, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 100,000 | $1.1M | 6.5% | Routine | SEC |
| Sep 10, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 100,000 | $1.1M | 6.5% | Routine | SEC |
| Aug 26, 2024 | Thompson Peter A. | Director | Form 4 sale | 83,695 | $1.1M | 100.0% | Unusual | SEC |
| Aug 26, 2024 | Orbimed Capital LLC | Director | Form 4 sale | 83,695 | $1.1M | 100.0% | Unusual | SEC |
| Aug 23, 2024 | Thompson Peter A. | Director | Form 4 sale | 868,682 | $11.5M | 91.2% | Unusual | SEC |
| Aug 23, 2024 | Orbimed Capital LLC | Director | Form 4 sale | 868,682 | $11.5M | 91.2% | Unusual | SEC |
| Aug 20, 2024 | Dorsey Brian | Chief Operating Officer | Form 4 sale | 50,000 | $750k | 89.2% | Routine | SEC |
| Aug 20, 2024 | Scott Kathleen D. | Chief Financial Officer | Form 4 sale | 12,500 | $200k | 48.6% | Routine | SEC |
| Aug 20, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 100,000 | $1.5M | 6.3% | Routine | SEC |
| Aug 20, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 100,000 | $1.5M | 6.3% | Routine | SEC |
| Aug 19, 2024 | Karas Eric | Chief Commercial Officer | Form 4 sale | 10,000 | $140k | 63.7% | Routine | SEC |
| Aug 13, 2024 | Dorsey Brian | Chief Operating Officer | Form 4 sale | 30,000 | $390k | 83.3% | Routine | SEC |
| Aug 13, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 100,000 | $1.2M | 6.1% | Routine | SEC |
| Aug 13, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 100,000 | $1.2M | 6.1% | Routine | SEC |
| Jul 16, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 100,000 | $1.1M | 5.9% | Routine | SEC |
| Jul 16, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 100,000 | $1.1M | 5.9% | Routine | SEC |
| Jul 9, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 100,000 | $962k | 5.7% | Routine | SEC |
| Jul 9, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 100,000 | $962k | 5.7% | Routine | SEC |
| Jun 12, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 100,000 | $914k | 5.6% | Routine | SEC |
| Jun 12, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 100,000 | $914k | 5.6% | Routine | SEC |
| May 16, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 100,000 | $906k | 5.4% | Routine | SEC |
| May 16, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 100,000 | $906k | 5.4% | Routine | SEC |
| May 7, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 100,000 | $934k | 5.3% | Routine | SEC |
| May 7, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 100,000 | $934k | 5.3% | Routine | SEC |
| Apr 16, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 100,000 | $928k | 5.1% | Routine | SEC |
| Apr 16, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 100,000 | $928k | 5.1% | Routine | SEC |
| Apr 9, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 100,000 | $928k | 5.0% | Routine | SEC |
| Apr 9, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 100,000 | $928k | 5.0% | Routine | SEC |
| Mar 25, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 97,610 | $890k | 4.8% | Routine | SEC |
| Mar 25, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 97,610 | $890k | 4.8% | Routine | SEC |
| Mar 21, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 2,390 | $22k | 0.1% | Routine | SEC |
| Mar 21, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 2,390 | $22k | 0.1% | Routine | SEC |
| Mar 15, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 100,000 | $914k | 4.8% | Routine | SEC |
| Mar 15, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 100,000 | $914k | 4.8% | Routine | SEC |
| Feb 29, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 3,782 | $34k | 0.2% | Routine | SEC |
| Feb 29, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 3,782 | $34k | 0.2% | Routine | SEC |
| Feb 28, 2024 | Tanimoto Sarina | CHIEF MEDICAL OFFICER | Form 4 sale | 99,478 | $897k | 5.4% | Routine | SEC |
| Feb 28, 2024 | Lowenthal Richard E | PRESIDENT AND CEO | Form 4 sale | 99,478 | $897k | 5.4% | Routine | SEC |
| Feb 26, 2024 | Tanimoto Sarina | Officer, Member of immediate family of any of the foregoing | Form 144 notice | 400,000 | $3.6M | Notice | SEC | |
| Feb 26, 2024 | Lowenthal Richard E | Officer, Director, Member of immediate family of any of the foregoing | Form 144 notice | 400,000 | $3.6M | Notice | SEC | |
| Sep 1, 2023 | Shawver Laura | Director | Form 4 sale | 100,000 | $771k | 32.2% | Routine | SEC |
| Sep 1, 2023 | Shawver Laura | Director | Form 144 notice | 100,000 | $771k | Notice | SEC | |
| Aug 4, 2023 | Shawver Laura | Director | Form 4 sale | 45,004 | $316k | 17.6% | Routine | SEC |
| Aug 2, 2023 | Shawver Laura | Director | Form 4 sale | 54,996 | $392k | 20.7% | Routine | SEC |
| Aug 1, 2023 | Shawver Laura | Director | Form 144 notice | 100,000 | $720k | Notice | SEC | |
| Jul 7, 2023 | Shawver Laura | Director | Form 4 sale | 8,858 | $56k | 4.0% | No plan | SEC |
| Jul 6, 2023 | Shawver Laura | Director | Form 4 sale | 91,142 | $590k | 30.2% | Unusual | SEC |
| Jul 3, 2023 | Shawver Laura | Director | Form 144 notice | 100,000 | $668k | Notice | SEC | |
| Jun 2, 2023 | Shawver Laura | Director | Form 4 sale | 100,000 | $684k | 32.2% | Routine | SEC |
| Jun 1, 2023 | Shawver Laura | Director | Form 144 notice | 100,000 | $680k | Notice | SEC | |
| May 9, 2023 | Shawver Laura | Director | Form 4 sale | 143,896 | $781k | 40.6% | Routine | SEC |
| May 8, 2023 | Shawver Laura | Director | Form 144 notice | 100,000 | $620k | Notice | SEC |